Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of recurrent glioblastoma with sunitinib (SU11248): phase 2 trial with translational biological and imaging study
2008-005169-78Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in glioblastoma (GBM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Primary efficacy of sunitinib in recurrent glioblastoma and Tolerance profile of sunitinib. Started Dec 2008; status: active.
02
Drugs
sunitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-005169-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005169-78.